Andrew A. Smith - 30 Jun 2025 Form 3/A - Amendment Insider Report for Medicus Pharma Ltd. (MDCX)

Reporting relationship: Chief Operating Officer
Issuer ticker: MDCX
Reported as of: 30 Jun 2025
Net transaction value: $0
SEC form: 3/A - Amendment
Accepted by SEC: 06 Aug 2025, 16:36:34 UTC
Original report date: 03 Jul 2025
Next SEC filing: 18 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew A. Smith

Key filing fact

Andrew A. Smith filed Form 3/A - Amendment for Medicus Pharma Ltd. (MDCX) on 06 Aug 2025.

Key facts

This page summarizes Andrew A. Smith's Form 3/A - Amendment filing for Medicus Pharma Ltd. (MDCX).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Aug 2025, 16:36.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001309614 Primary reporting owner

Smith Andrew Alasdair

Relationship: Chief Operating Officer
Address: 300 CONSHOHOCKEN STATE ROAD, SUITE 200, W. CONSHOHOCKEN
Signature: /s/ Andrew A. Smith
Signature date: 06 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDCX holding

Common Shares, no par value ("Common Shares")

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 164
Date: 30 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDCX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 30 Jun 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 100,000
Exercise price: $2.60
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This amendment is being filed to include Common Shares that were inadvertently omitted from the Form 3 filed by the Reporting Person on July 3, 2025.

Footnote F2

The board of directors of Medicus Pharma Ltd. (the "Board") approved, during a Board meeting held on July 22, 2025, accelerated vesting of the Reporting Person's options that were otherwise unvested and scheduled to vest annually in five equal installments beginning on June 30, 2026. All these options are now vested.